OTCMKTS:MKKGY Merck KGaA (MKKGY) Stock Price, News & Analysis $29.81 +0.12 (+0.39%) As of 12:35 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesShort InterestBuy This Stock About Merck KGaA Stock (OTCMKTS:MKKGY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Merck KGaA alerts:Sign Up Key Stats Today's Range$29.81▼$30.1050-Day Range$23.76▼$29.6952-Week Range$23.73▼$31.00Volume15,542 shsAverage Volume117,175 shsMarket Capitalization$19.26 billionP/E Ratio13.25Dividend Yield1.17%Price TargetN/AConsensus RatingHold Company Overview Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co.; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY. Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility. The Life Science division supplies reagents, lab consumables, filtration and chromatography solutions, and bioprocessing technologies to research institutions and biopharmaceutical manufacturers — operations that include the MilliporeSigma brand in the United States and Canada following the acquisition of Sigma‑Aldrich. The Electronics business produces high‑performance materials and specialty chemicals used in semiconductor fabrication, display technologies and other advanced industrial applications. The company operates globally, serving customers across Europe, the Americas, Asia and other regions through manufacturing sites, research centers and commercial affiliates. Since May 2021 Merck KGaA has been led by Chair of the Executive Board and CEO Belén Garijo. Merck emphasizes integrated R&D and partnerships to support pharmaceutical development, laboratory science and materials innovation, positioning itself as a diversified supplier to healthcare, research and high‑technology industries.AI Generated. May Contain Errors. Read More Merck KGaA Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreMKKGY MarketRank™: Merck KGaA scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingMerck KGaA has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageMerck KGaA has only been the subject of 1 research reports in the past 90 days.Read more about Merck KGaA's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth9.84% Earnings GrowthEarnings for Merck KGaA are expected to grow by 9.84% in the coming year, from $1.83 to $2.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merck KGaA is 13.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Merck KGaA is 13.36, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.96.Price to Earnings Growth RatioMerck KGaA has a PEG Ratio of 2.58. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMerck KGaA has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Merck KGaA's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Merck KGaA has been sold short.Short Interest Ratio / Days to CoverMerck KGaA has a short interest ratio ("days to cover") of 0.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Merck KGaA has recently decreased by 42.06%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldMerck KGaA pays a meaningful dividend of 1.22%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthMerck KGaA does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Merck KGaA is 15.56%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Merck KGaA will have a dividend payout ratio of 17.41% next year. This indicates that Merck KGaA will be able to sustain or increase its dividend.Read more about Merck KGaA's dividend. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Merck KGaA this week, compared to 2 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Merck KGaA insiders have not sold or bought any company stock.Percentage Held by Institutions0.10% of the stock of Merck KGaA is held by institutions.Read more about Merck KGaA's insider trading history. Receive MKKGY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merck KGaA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MKKGY Stock News HeadlinesFirst patient dosed in Merck’s Phase III PROCEADE-CRC-03 trial for mCRC3 hours ago | yahoo.comDeutsche Bank Keeps Their Hold Rating on Merck KGaA (0O14)May 16, 2026 | theglobeandmail.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.May 22 at 1:00 AM | Profits Run (Ad)Merck KGaA (MKKGY) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comMerck KGaA lifts 2026 profit outlook on demand for lab suppliesMay 13, 2026 | reuters.comMerck KGaA (MKKGY) Projected to Post Earnings on WednesdayMay 11, 2026 | americanbankingnews.comThe top 5 analyst questions from Merck’s Q1 earnings callMay 7, 2026 | msn.comMerck KGaA doses first patient in Phase III programme of enpatoranMay 1, 2026 | yahoo.comSee More Headlines MKKGY Stock Analysis - Frequently Asked Questions How have MKKGY shares performed this year? Merck KGaA's stock was trading at $28.68 at the start of the year. Since then, MKKGY stock has increased by 4.8% and is now trading at $30.07. How were Merck KGaA's earnings last quarter? Merck KGaA (OTCMKTS:MKKGY) posted its quarterly earnings results on Wednesday, May, 13th. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.14. The company earned $6.03 billion during the quarter, compared to analyst estimates of $5.93 billion. Merck KGaA had a trailing twelve-month return on equity of 8.93% and a net margin of 12.07%. How do I buy shares of Merck KGaA? Shares of MKKGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/13/2026Today5/22/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolOTCMKTS:MKKGY Previous SymbolOTCMKTS:MKKGY CIKN/A Webwww.merckgroup.com Phone496151720Fax49-61-5172-2000Employees62,461Year Founded1668Profitability EPS (Trailing Twelve Months)$2.25 Trailing P/E Ratio13.25 Forward P/E Ratio16.29 P/E Growth2.58Net Income$2.95 billion Net Margins12.07% Pretax Margin15.68% Return on Equity8.93% Return on Assets5.13% Debt Debt-to-Equity Ratio0.37 Current Ratio1.46 Quick Ratio0.96 Sales & Book Value Annual Sales$23.87 billion Price / Sales0.81 Cash Flow$8.92 per share Price / Cash Flow3.34 Book Value$50.18 per share Price / Book0.59Miscellaneous Outstanding Shares646,210,000Free FloatN/AMarket Cap$19.26 billion OptionableNot Optionable Beta0.97 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:MKKGY) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredOne filing just changed the SpaceX IPO foreverSpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the larges...Behind the Markets | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck KGaA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.